Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...

Novartis has a lot cooking with new drug launches, and the company is not letting potential U.S. tariffs on pharmaceuticals ...

Persistence has paid off for Abeona Therapeutics and its gene therapy for recessive dystrophic epidermolysis bullosa (RDEB).

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...

A paper published this month in the journal Current Addiction Reports discusses the merits of intranasal medications that can ...

Bayer has overturned a ruling that it brought discredit on the pharma industry. | Bayer has overturned a ruling that it ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...

Not letting its expansion efforts idle, contract manufacturer PCI Pharma Services is picking up a 100% stake in Ajinomoto's ...

Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the ...

As an unplanned overall survival (OS) analysis of ivonescimab’s Keytruda head-to-head trial rocked the PD- (L)1xVEGF world, ...

After issues at a third-party manufacturer caused the FDA to reject Regeneron's multiple myeloma bispecific antibody ...